123results about "Protozoa material medical ingredients" patented technology

Storage stable compositions of biological materials, including bioactive biological materials are provided in the form of a water-in-oil emulsion, comprising:(a) cellular material selected from living and / or dormant prokaryotic and / or eukaryotic cells and tissues, the cellular material being compatible with water-in-oil emulsions;(b) one or more oils selected from vegetable oils and fish oils;(c) an oil-soluble nonionic polymeric surfactant having a molecular weight of from about 2500 to about 15000; and(d) water.The compositions may also contain a thickener such as a hydrophobic fumed silica or bentonite.Compositions may be used for various purposes, depending on the contained biological material. Specific examples include compositions containing Fusarium lateritium control of Eutypa lata in plant wounds made by cutting or pruning, and compositions containing Lagenidium giganteum for control of mosquitoes.

The present invention features a unique, natural formulation and method of administering the same to treat and prevent diabetes, or rather advances treatment of diabetes, by providing a naturaceutical composition or treatment formulated with one or more processed Morinda citrifolia products as derived from the Indian Mulberry plant. The Morinda citrifolia is particularly adapted to treat Type II diabetes. The Morinda citrifolia product is preferably a leaf extract, but may also be in the form of a juice, a puree juice, a dietary fiber, or other similar forms and is incorporated into various carriers or naturaceutical compositions suitable for in vivo treatment of a patient. The naturaceutical may also combine other food products into the naturaceutical, such as fruit juices, dietary supplements, vitamins and minerals, and others.

The present invention relates to amoebae (slime molds) and uses thereof. In particular, the present invention relates to the use of amoebae or their environmentally stable spores to treat microbial infections and other uses.

The present invention is directed to isolated Bacillus subtilis, Pseudomonas putida, and Sporobolomyces roseus which are useful as a biocontrol agent. These organisms are useful in a method of imparting to plants protection against plant pathogens by applying them to plants, plant seeds, or soil surrounding plants under conditions effective to impart disease protection to the plants or plants produced from the plant seeds. The biocontrol agents are also useful in a method of enhancing plant growth which involves applying them to plants, plants seeds, or soil surrounding plants under conditions effective to enhance growth in the plants or plants produced from the plant seeds.

A dry composition-of-matter and a kit including dehydrated stinging capsules and methods of producing and using same are provided.

Disclosed are apparatuses and methods for the production of attenuated aseptic parasites in haematophagous insects generally, and production of Plasmodium species sporozoites in Anopheles species mosquitoes specifically; apparatuses and methods for the production of strains of haematophagous insects with desired properties such as hypoallergenicity or hyperinfectivity; methods of producing a parasite strain that is capable of withstanding cyropreservation at temperatures close to freezing; apparatuses and methods for the injection of an attenuated parasite vaccine; production of parasites and haematophagous insects that are free from contamination by unwanted biological agents; apparatuses for the reconstruction of complex parasitic life cycles aseptically to avoid the contamination of the parasite or the insect vector host with unwanted biological agents.

The present invention relates to amoebae (slime molds) and uses thereof. In particular, the present invention relates to the use of amoebae or their environmentally stable spores to treat microbial infections and other uses.

The present invention provides a particle comprising a polypeptide and at least one malaria antigen, and a composition or vaccine comprising thereof, its use in medicine, particularly in the prevention or treatment of malaria infections.

The present invention provides a novel use of coccidian, specifically relates to the use of coccidian as a vaccine live vector. The present invention further provides a live vaccine with coccidian as a vector, which is transgenic coccidian capable of expressing exogenous protein or stably transfected coccidian that contain expression vector and can express exogenous coccidian. The present coccidian vector live vaccine can induce organisms to simultaneously generate protective humoral and cellular immune responses (including the mucosal immune response), as well as generate memory responses, which can be readily carried out and has stable effect and high biological safety without generating immune tolerance.

The present invention relates to a process for producing arachidonic acid. In one embodiment, Mortierella sect. schmuckeri microorganisms are cultured in fermentation medium, preferably containing a component of a complex nitrogen source. Further disclosed is a food product which includes Mortierella sect. schmuckeri microorganisms or lipid isolated from such microorganisms to enhance the arachidonic acid content of the food product.

The present invention relates to Dictyostelids myxamoebae of phylum Mycetozoa and uses thereof. In particular, the present invention relates to the use of amoebae, slugs, or their environmentally stable spores to treat microbial infections and other uses.

The invention relates to T. cruzi trans-sialidase (TS) and to the neurotrophic and IL-6 secretion-inducing activities of the protein. TS, neurotrophic variants and / or neurotrophic peptides based upon the sequence of TS can be administered to a mammal to directly or indirectly provide neurotrophic support for neurons. A mammalian neurotrophic factor (e.g., CNTF, LIF) can be co-administered with the TS, neurotrophic variant and / or neurotrophic peptide. TS, IL-6 secretion-inducing variants and / or IL-6 secretion-inducing peptides based upon the sequence of TS can be administered to a mammal to induce the secretion of IL-6. TS, active variants and / or active peptides can be administered to a mammal having an acquired or congenital condition characterized by neuronal degeneration or to a mammal that has experienced trauma to the brain, spinal cord or peripheral nerves. The invention also relates to neurotrophic and IL-6 secretion-inducing variants of TS and to neurotrophic and IL-6 secretion-inducing peptides. The invention also relates to compositions comprising TS, active variants thereof and / or active peptides and a physiologically acceptable carrier.